Get the Stockscreener App
16.44
1.67%
0.27
Lb Pharmaceuticals Inc stock is traded at $16.44, with a volume of 42,728.
It is up +1.67% in the last 24 hours and up +9.24% over the past month.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
See More
Previous Close:
$16.17
Open:
$15.93
24h Volume:
42,728
Relative Volume:
0.50
Market Cap:
$330.63M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.78%
1M Performance:
+9.24%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$15.85
$16.55
1-Week Range:
$15.05
$16.95
52-Week Range:
$13.36
$17.50
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Compare LBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
16.44 | 362.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.15 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.59 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.86 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
841.58 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.94 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
LB Pharmaceuticals Inc Rings the Closing Bell - Nasdaq
LB Pharmaceuticals Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement - Bloomberg.com
LB Pharmaceuticals Inc (LBRX) Recent Insider Transactions - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Latest Press Releases & Corporate News - Yahoo
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo! Finance Australia
Anna Eramo Net Worth (2025) - GuruFocus
Rebecca Luse Net Worth (2025) - GuruFocus
Zachary Prensky Net Worth (2025) - GuruFocus
LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs - MSN
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs - GlobeNewswire
LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Inc Appoints James Rawls as Senior Vice President of Regulatory Affairs - MarketScreener
LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs - Investing.com
LB Pharmaceuticals Inc’s Quiet Period Set To End on October 21st (NASDAQ:LBRX) - Defense World
LB Pharmaceuticals Inc's Quiet Period Set To End on October 21st (NASDAQ:LBRX) - MarketBeat
Analysts Set LB Pharmaceuticals Inc (NASDAQ:LBRX) PT at $30.50 - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Raised to Hold at Zacks Research - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Biopharma financings climb to $18.7B in the third quarter - BioWorld MedTech
Q3 Earnings Forecast for LBRX Issued By Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
September biopharma financings jump 54% to $7.12B - BioWorld MedTech
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded at Leerink Partnrs - MarketBeat
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms - Sahm
Drug developer MapLight eyes $704.3 million valuation in US IPO - Reuters
LB Pharmaceuticals to Present Three Posters at 38th ECNP - GlobeNewswire
Leerink Partners Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $34 - 富途牛牛
Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential - TipRanks
Leerink Partners Initiates LB Pharmaceuticals at Outperform With $34 Price Target - MarketScreener
0.66 effect size in cognition: LB Pharma's LB‑102 shows dose‑dependent gains; 3 ECNP posters Oct 11-14 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Leerink Partners - MarketBeat
LB Pharmaceuticals stock initiated at Outperform by Leerink Partners - Investing.com
Promising Prospects for LB Pharmaceuticals: Buy Rating Affirmed on LB-102’s Market Potential - TipRanks
Piper Sandler initiates coverage on LB Pharmaceuticals stock with Overweight rating - Investing.com
Stifel initiates coverage on LB Pharmaceuticals stock with Buy rating - Investing.com
LB Pharmaceuticals IncCommon Stock (Nasdaq:LBRX) Stock Quote - FinancialContent
LB Pharmaceuticals Appoints William Kane and Rekha Hemrajani To Board - citybiz
LB Pharmaceuticals adds two directors following Nasdaq debut By Investing.com - Investing.com Nigeria
LB Pharmaceuticals adds two directors following Nasdaq debut - Investing.com India
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - The Manila Times
Strategic Board Expansion: LB Pharmaceuticals Strengthens Leadership for Phase 3 Schizophrenia Drug Trial - Stock Titan
Scoop: Voltron Therapeutics plans IPO next year - Axios
Deep Track Capital, LP Acquires Significant Stake in LB Pharmaceuticals Inc - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pha - GuruFocus
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuti - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in LB Pharmace - GuruFocus
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
There is no financial data for Lb Pharmaceuticals Inc (LBRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.70%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):